Docs Who Lift Zepbound versus Wegovy
18 snips
May 12, 2025 Discover the battle of weight loss medications with tirzepatide showing superior effectiveness over semaglutide. Unpack the complexities of drug pricing and the critical need for affordable access to treatments for severe obesity. Gender influences on weight loss outcomes are explored, alongside the safety and tolerability of these medications. Long-term studies reveal promising benefits beyond weight loss, including improvements in metabolic health. Get the scoop on future research directions, particularly regarding cardiovascular impacts.
AI Snips
Chapters
Transcript
Episode notes
Tirzepatide Outperforms Semaglutide
- Tirzepatide (Zepbound) causes significantly more weight loss than semaglutide (Wegovy).
- Around 50% of tirzepatide users lost 20%+ body weight, compared to 27% with semaglutide.
Prescribing Guidance for Obesity
- Prioritize prescribing potent weight loss meds to patients with severe obesity and complications.
- Use cost-effectiveness to guide decision-making in clinical practice.
Cost-Effectiveness in Obesity Therapy
- Cost-effectiveness should guide prescribing weight-loss meds, favoring expensive options for severe obesity.
- The greatest benefits occur in patients with severe obesity and complications.